Lilly and Boehringer’s Type II Diabetes Drug Gets Expanded Approval from FDA for Use in Children
Eli Lilly and Boehringer Ingelheim secured approval from the US Food and Drug Administration (FDA) to expand the indications of its diabetes drug Jardience. The new indications include children under 10 with type 2 diabetes, a growing population in recent years. The drug would be the first in its class for patients in this age group, opening up a new avenue for early life diabetes management.
New Vertex Cell Therapy for Diabetes to Hit the Clinic Soon
Shortly after receiving the nod from the US Food and Drug Administration (FDA), Vertex Pharma announced that it will soon bring its new application of its diabetes cell therapy to clinics by summer of this year. The therapy uses a special delivery method that removes the need for immune suppressants after delivering stem cells that can restore the function of insulin-producing pancreatic cells.
Eli Lilly CFO Talks Splitting Tirzepatide into Two Brands for Obesity and Diabetes
In a talk at the Morgan Stanley healthcare conference this week, Eli Lilly’s CFO Anat Ashkenazi spoke about the company’s deliberations in deciding whether to split Tirzepatide into two brands, one for diabetes and one for obesity. Lilly has done this before with Prozac (fluoxetine), making a new brand for premenstrual dysphoric disorder. It did not do the same for the drug Cialis, an erectile dysfunction drug also indicated for benign prostatic hyperplasia.
AJMC Article: Addressing Healthcare Disparities and Managed Care Considerations With Continuous Glucose Monitoring
Continuous glucose monitoring is associated with better outcomes for people living with diabetes. Unfortunately, this technology is not accessible to many patients, worsening outcomes for marginalized. In a newly published article in AJMC, the barriers to continuous glucose monitoring are laid out and ways to address these disparities are put forward. The role of insurance is highlighted.
New RWE Study Unveals Full Range of Medical Needs of Patients with Diabetes
A paper published in the journal eClinical Medicine explores the scope of illnesses patients in Europe with type II diabetes face. The study, which pulled data from around 224,000 patients with diabetes from North-West London, found that patients were most likely to present with one or more of five conditions when diagnosed as diabetic. The data came from the Discovery-NOW data set, which contains electronic health records (EHR) data from 2.5 million patients.
Study: Fragmentation of US Healthcare and Policy Negatively Impacts Diabetes Outcomes
Despite wide-ranging efforts in the US to reduce the incidence and morbidity associated with type 2 diabetes, progress has stalled, [...]
FDA Approves Eli Lilly Diabetes Drug
The US Food and Drug Administration (FDA) has given the green light to Eli Lilly’s new type II diabetes therapy [...]
ICER: Final Evidence Report and Policy Recommendations on Tirzepatide Now Available
The Institute for Clinical and Economic Review (ICER) just released their final evidence report on the diabetes 2 drug terzepatide. [...]
Determining the Value of Continuous Glucose Monitoring
Continuous glucose monitoring (CGM) offers the potential for better diabetes management, but determining the value for patients, payers, and providers [...]
Novo Nordisk Lowers Costs of Insulin Amid Pandemic
Novo Nordisk is extending a hand to diabetes patients amid the COVID-19 pandemic, according to a STAT report. According to [...]
U.S. Looks to Limit Out-of-Pocket Costs for Insulin Under Medicare
The Trump administration announced a new plan to limit the out-of-pocket costs for insulin to $35 month for Medicare patients, [...]
Dems Invite Insulin Affordability Advocates to State of the Union
A slate of Democratic legislators have invited insulin affordability activists as their guests to tonight's State of the Union address, [...]
CVS Caremark Plan Looks to Nix Costs for Diabetes Drugs
CVS Caremark's newest option, RxZERO, looks to nix out-of-pocket costs for diabetes drugs through a number of strategies, including nudging [...]
Dems Pivot to Insulin, Illinois Caps Insulin Prices
Democratic presidential candidates during a campaign stop in Iowa made clear their frustration over U.S. insulin prices, STAT reports. During [...]
Lilly Exec Talks Insulin Market
Pharmalot recently caught up with Mike Mason, head of Eli Lilly's diabetes branch, to discuss the drugmaker's generic alternative to [...]
How Artificial Intelligence and Real World Data Can Improve the Management of Type 2 Diabetes: A Case Study
See how Veradigm, a business unit of Allscripts focused on generating data-driven healthcare insights using EHR data applied artificial intelligence to EHRs to improve therapeutic management of patients with concordant comorbidities who are living with type 2 diabetes.
A Brief History of Diabetes Simulation Modelling and the Mt Hood Challenge
Why is a diabetes and economics simulation modelling conference named after a mountain? Back in 1999, two groups who developed [...]
Diabetes Trends in the U.S.
PATIENT AWARENESS AND IMPACT ON OUTCOMES Diabetes is one of the most prevalent, costly, and burdensome diseases in the world, [...]
Adding value to biomedical endpoints – The Importance of Patient Reported Outcomes (PROs)
The challenges A key hurdle facing the entire pharmaceutical industry is non-adherence by patients to medication. This problem is only [...]
